CIHR – ICR Late Breaking Funding Opportunity

ICR is pleased to announce a Recent Partnership with AstraZeneca (AZ) to develop the independence of New Investigators in initiating and conducting research in the area of metastatic bladder cancer.

This partnership will provide funding for one award, for an Early Career Investigator to support research in the area of locally advanced or metastatic bladder cancer.

The maximum amount per award is $115,000 per year for up to three (3) years for a total of $345,000 per for this award.

  • Of this $115,000:
    • Salary contribution: up to a maximum of 40% or $46,000 per annum, including fringe benefits can be requested;
    • Research Allowance: a minimum of 60% or $69,000 per annum must be requested.

Details on how to apply can be found at the link below. Important note: Information on the addition of the metastatic bladder cancer pool will be updated shortly.’